Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium. Schuler M, et al. Among authors: fischer jr. Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17. Oncologist. 2014. PMID: 25232040 Free PMC article.
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E, Thöm I, Krüll A, Engel-Riedel W, Müller T, Meissner C, Dürk H, Fischer J, Gütz S, Kortsik C, Elbers M, Schuch G, Andritzky B, Görn M, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C. Laack E, et al. Lung Cancer. 2007 Aug;57(2):181-6. doi: 10.1016/j.lungcan.2007.03.001. Epub 2007 Apr 17. Lung Cancer. 2007. PMID: 17442447 Clinical Trial.
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R. Gottschling S, et al. Among authors: fischer jr. Lung Cancer. 2012 Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7. Lung Cancer. 2012. PMID: 22483783
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, Reck M, Fischer JR. Heigener DF, et al. Among authors: fischer jr. Lung Cancer. 2013 Jun;80(3):319-25. doi: 10.1016/j.lungcan.2013.02.007. Epub 2013 Mar 20. Lung Cancer. 2013. PMID: 23522488 Clinical Trial.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators. Paz-Ares L, et al. Among authors: fischer jr. Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701171 Free article. Clinical Trial.
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, Schenk M, Schröder M, Villalobos M, Reinmuth N, Penzel R, Schnabel P, Acker T, Reuss A, Wolf M; ABC-Lung Cancer Group. Thomas M, et al. Eur Respir J. 2015 Jul;46(1):219-29. doi: 10.1183/09031936.00229014. Epub 2015 Mar 18. Eur Respir J. 2015. PMID: 25792638 Free article. Clinical Trial.
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators. Kreuter M, et al. Among authors: fischer jr. J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014. J Thorac Oncol. 2016. PMID: 26762743 Free article. Clinical Trial.
280 results